Azapropazone
MUSCULO-SKELETAL SYSTEM
Also known as: AHR-3018, apazone, apazone dihydrate, azapropazone dihydrate, cinnamin, cinnopropazone, prolixan
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Azapropazone is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1972. DrugCentral lists 2 molecular targets, including PTGS1 and XDH. Recorded indications include Ankylosing spondylitis, Gout, Osteoarthritis and Rheumatoid arthritis.
- Molecular targets: PTGS1 and XDH (2 listed in DrugCentral).
- Indications: Ankylosing spondylitis, Gout, Osteoarthritis and Rheumatoid arthritis.
- ATC code: M01AX04 (Other antiinflammatory and antirheumatic agents, non-steroids).
- Molecular formula: C16H20N4O2; molecular weight 300.36 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (4)
- Ankylosing spondylitis
- Gout
- Osteoarthritis
- Rheumatoid arthritis
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | PTGS1 | unknown | — |
| Xanthine dehydrogenase/oxidase | XDH | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1972-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
M01AX04 | MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Other antiinflammatory and antirheumatic agents, non-steroids |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Azapropazone is on its molecule page.
| Molecular formula | C16H20N4O2 |
|---|---|
| Molecular weight | 300.36 g/mol |
| CAS number | 13539-59-8 |
| InChIKey | MPHPHYZQRGLTBO-UHFFFAOYSA-N |
| PubChem CID | 26098 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Azapropazone used for?
DrugCentral lists the following indications for Azapropazone: Ankylosing spondylitis, Gout, Osteoarthritis and Rheumatoid arthritis.
How does Azapropazone work?
Its molecular targets in DrugCentral include PTGS1 and XDH.
When was Azapropazone first approved?
Azapropazone was first approved by the YEAR INTRODUCED in 1972.
What is the chemical formula of Azapropazone?
Azapropazone has the molecular formula C16H20N4O2 and a molecular weight of 300.36 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 266 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1565476 — compound record and bioactivity
- PubChem CID 26098 — chemical identifiers
- DrugBank DB07402 — drug record
- FDA UNII BF18764H96 — substance identity
- UniProt P23219 (PTGS1) — target protein
- UniProt P47989 (XDH) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.